Literature DB >> 12136056

Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke.

E E Smith1, J Rosand, K A Knudsen, E M Hylek, S M Greenberg.   

Abstract

BACKGROUND AND OBJECTIVES: Prior ischemic stroke is a risk factor for intracerebral hemorrhage (ICH) in patients taking warfarin, but the mechanism is not known. This study investigates radiographic and clinical characteristics of patients with warfarin-related ICH following ischemic stroke.
METHODS: In this case-control study, the authors selected all patients with warfarin-related ICH and previous symptomatic ischemic stroke from a prospective cohort of consecutive patients with ICH. Control subjects were similarly aged patients with history of symptomatic stroke randomly chosen from an anticoagulant therapy unit. The 26 eligible ICH cases and 56 controls were compared for vascular risk factors, stroke characteristics, and extent of leukoaraiosis (graded in anterior and posterior brain regions on a validated scale of 0 to 4).
RESULTS: The presence and severity of leukoaraiosis on CT scan correlated strongly with the occurrence of ICH. Leukoaraiosis was seen in 24 of 26 cases (92%) compared with 27 of 56 controls (48%), yielding an odds ratio of 12.9 (95% CI 2.8 to 59.8). Other clinical factors associated with ICH included an international normalized ratio >3.0, history of multiple previous strokes, and the presence of carotid artery stenosis. The relationship between leukoaraiosis and ICH persisted in multivariable analyses controlling for these risk factors as well as hypertension and diabetes mellitus.
CONCLUSIONS: Leukoaraiosis is an independent risk factor for warfarin-related ICH in survivors of ischemic stroke, including those in the commonly employed range of anticoagulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12136056     DOI: 10.1212/wnl.59.2.193

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  43 in total

1.  Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy.

Authors:  Andrea Rubboli; Cecilia Becattini; Freek Wa Verheugt
Journal:  World J Cardiol       Date:  2011-11-26

2.  Leukoaraiosis on magnetic resonance imaging is related to long-term poor functional outcome after thrombolysis in acute ischemic stroke.

Authors:  Jae Hyung Choi; Hyo-Jin Bae; Jae Kwan Cha
Journal:  J Korean Neurosurg Soc       Date:  2011-08-31

3.  Testing for CYP2C9 before initiating anticoagulant therapy.

Authors:  Oscar M P Jolobe
Journal:  J Gen Intern Med       Date:  2009-08       Impact factor: 5.128

Review 4.  Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates.

Authors:  Jeremy D Schmahmann; Eric E Smith; Florian S Eichler; Christopher M Filley
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 5.  Cerebral microbleeds and macrobleeds: should they influence our recommendations for antithrombotic therapies?

Authors:  Kellen E Haley; Steven M Greenberg; M Edip Gurol
Journal:  Curr Cardiol Rep       Date:  2013-12       Impact factor: 2.931

Review 6.  Clinical neurogenetics: stroke.

Authors:  Natalia S Rost
Journal:  Neurol Clin       Date:  2013-07-17       Impact factor: 3.806

Review 7.  [Difficult decisions in stroke therapy].

Authors:  M Endres; M Grond; W Hacke; M Ebinger; P D Schellinger; M Dichgans
Journal:  Nervenarzt       Date:  2011-08       Impact factor: 1.214

Review 8.  Mechanisms and treatment of ischaemic stroke--insights from genetic associations.

Authors:  Hugh S Markus; Steve Bevan
Journal:  Nat Rev Neurol       Date:  2014-10-28       Impact factor: 42.937

9.  Symptomatic intracerebral hematomas in posterior circulation stroke patients anticoagulated with heparin.

Authors:  Kyusik Kang; Byung-Woo Yoon
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

10.  Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study.

Authors:  Andrew M Demchuk; Firosh Khan; Michael D Hill; Philip A Barber; Brian Silver; Suresh Patel; Steven R Levine
Journal:  Cerebrovasc Dis       Date:  2008-06-17       Impact factor: 2.762

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.